Vivaldi Coelho Rogerio 4

What Happened Vivaldi Coelho Rogerio, a director of Crinetics Pharmaceuticals, was granted equity awards on June 18, 2026: 5,925 restricted stock units (RSUs) and rights to 9,730 derivative shares (a stock option-like award). Both awards were reported with an acquisition price of $0.00 (standard for compensatory grants). These are grants/awards (not purchases or sales) and represent compensation subject to vesting, not immediate open-market purchases.

Key Details

• Transaction date: 2026-06-18; Report filed: 2026-06-22.
• Awards: 5,925 RSUs (A) at $0.00; 9,730 derivative-share award (A, derivative) at $0.00 — total 15,655 aggregate rights.
• Reported cash value on the Form 4: $0 (compensatory grant reporting); fair value may be disclosed elsewhere (e.g., proxy or 10-K/8-K).
• Shares owned after the transaction: Not specified in this filing.
• Vesting/conditions (from footnotes):
  • F1 (RSUs): 100% vesting on the earlier of (a) the first anniversary of the grant date or (b) the next annual meeting of stockholders, subject to continued board service.
  • F2 (derivative award/option): Vests and becomes exercisable on the earlier of (a) the first anniversary of the grant date or (b) the next annual meeting, subject to continued board service.
• Filing timeliness: The report was filed four days after the reported transaction date; Form 4s are generally due within two business days, so this appears to be delayed.

Context These awards are typical director compensation and are contingent on continued service and vesting; RSUs convert to shares upon vesting, while the derivative award (per F2) must vest/be exercised to result in shares. Grants are informational and reflect company compensation practices rather than a direct buy/sell signal—purchases are usually more indicative of personal bullishness.